The gross proceeds to the Company from the ... developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need.

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

Idiopathic pulmonary fibrosis is a chronic, progressive, incurable lung disease, leading to irreversible lung tissue ...

The primary goal of the research will be to understand how dysfunctional lung epithelial cells contribute to causing and perpetuating pulmonary fibrosis, according to the release. These cells ...

"I was diagnosed with pulmonary fibrosis, which is the scarring of the lungs, which, when your lungs are scarred, it's harder for the oxygen to go to your blood, so your blood/oxygen levels drop ...